AMRI Announces Key Sales Executive Promotions

ALBANY, N.Y.--(BUSINESS WIRE)-- AMRI (NASDAQ: AMRI) today announced the following promotions of key members of its sales leadership team.

Dr. Mark Sawicki has been promoted to vice president of business development for Europe. As part of the company’s continuing strategy to increase European market share, Dr. Sawicki will drive the expansion and focus of AMRI’s European sales division by leading all sales activities to promote AMRI’s full spectrum of global scientific services, including drug discovery, development/small scale manufacturing, and large scale manufacturing. Previously, Dr. Sawicki was responsible for sales activities for AMRI discovery services in North America and Europe as senior director of business development. Dr. Sawicki joined AMRI in 2004 as director of business development.

Christopher Conway has been promoted to senior director of business development for North American Discovery Services. Mr. Conway will lead sales activities in North America to promote the company’s drug discovery services including the full spectrum of AMRI’s global integrated drug discovery platform. Prior to joining AMRI, Mr. Conway held sales positions of increasing responsibility at Johnson & Johnson, culminating in the role of district manager for Johnson & Johnson’s Ortho-McNeil Neurologics Division. Mr. Conway joined AMRI in 2008 as manager of business development.

Angie Urdanoff has been promoted to senior director, sales operations and will have increased oversight for driving the company’s global sales operations efforts. Before joining AMRI, Ms. Urdanoff worked for Pitney Bowes Business Insight as managing director of Americas sales operations. Prior to that, she served as product and manufacturing manager for GE Silicones. She was awarded GE’s Six Sigma Black Belt certification in 1996. She joined AMRI in 2009 as director of sales operations.

“We are pleased to announce the promotions of these individuals who have made significant contributions to AMRI’s sales organization,” said Chairman, CEO and President Thomas E. D’Ambra, Ph.D. “As AMRI continues to add locations and expand the breadth of its products and services, we are also increasing the scope of our sales activities with the goal of expanding our market share. We are proud to recognize the contributions of these key individuals, congratulate them on this important step, and wish them great success in their new roles.”

About AMRI

Founded in 1991, Albany Molecular Research, Inc. provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world’s leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.

Forward-Looking Statement

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words and include, without limitation, statements regarding the company's clinical development plans for its proprietary compounds, the company’s research programs and the license arrangement with BMS concerning the company’s biogenic amines program. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to delay or denial of approvals from the FDA, potential changes in the cost, scope and duration of clinical trials as compared to the company’s current expectations, the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2009 as filed with the Securities and Exchange Commission on March 12, 2010 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.



CONTACT:

Media
AMRI
Andrea Schulz, 518-512-2226
Director of Corporate Communications
or
Investors
Peter Jerome, 518-512-2220
Director of Investor Relations

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  Manufacturing  Chemicals/Plastics  Other Manufacturing  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.